吉非替尼

结论：以EGFR为靶点的DNA疫苗和靶向药物吉非替尼之间具有协同性抗肿瘤作用，DNA疫苗主动免疫可以提高吉非替尼的疗效。

Conclusion : DNA vaccine targeting EGFR has a synergistic effect with gefitinib in antitumor activity , and this DNA vaccine can increase the efficiency of gefitinib .

目的观察吉非替尼单药治疗对晚期非小细胞肺癌（NSCLC）老年患者的效果和安全性。

Objective To evaluate the efficacy and safety of gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer ( NSCLC ) .

南美响尾蛇神经毒素联合吉非替尼对人肺腺癌A549细胞的作用

Effects of Crotoxin Combined with Iressa on A549 Cells

因此，检测大肠癌EGFR外显子突变也为将吉非替尼疗应用于大肠癌提供理论依据。

Therefore , it would also provide necessary evidence to test EGFR mutations for the use of Gefitinib in CRCs .

结果他们惊奇地发现，几乎所有对吉非替尼治疗具有较好反应的患者的肿瘤细胞都携带结构发生了改变的EGFR。

As a result , they were surprised to find that almost all of the auspicious , with good treatment for patients with tumor cells of the reaction have a change in the structure of EGFR .

吉非替尼（gefitinib，Iressa，zD1839）是一种口服选择陛表皮生长因子受体酪氨酸激酶抑制剂。

Gefitinib ( Iressa , ZD1839 ) is a selective EGFR-TK ( epidermal growth factor recep-tor tyrosine kinase ) inhibitor .

吉非替尼（Iressa，ZD1839）治疗晚期非小细胞肺癌的疗效及安全性评价

Evaluation of Safety and Efficacy of Gefitinib ( 'Iressa ' , Zd1839 ) as a Treatment for Advanced Non-Small-Cell Lung Cancer

病人是女性也与对吉非替尼有反应显著相关。

Being female was also significantly associated with response to gefitinib .

结论：吉非替尼耐药细胞HT-29/ZD不存在与传统化疗药物相似的多药耐药性；

Conclusion : HT-29 / ZD has no multi-drug resistance like traditional anticancer drugs .

吉非替尼治疗晚期肺腺癌的疗效和毒副作用

Factors Contributed to Anticancer and Adverse Effects in Advanced Adenocarcinoma of Lung with Iressa

吉非替尼对于化疗失败的晚期肺腺癌的疗效及生存观察吉西他滨联合顺铂与长春瑞滨联合顺铂治疗晚期肺腺癌的比较

Clinical observation of gemcitabine with cisplatin and navelbine with cisplatin in the treatment of patients with advanced lung adenocarcinoma

结论：与安慰剂相比较，中国的局部晚期非小细胞肺癌患者接受吉非替尼维持治疗后无进展生存显著延长。

Conclusions : PFS was significantly longer with G compared with P as maintenance therapy in Chinese patients with locally advanced NSCLC .

吉非替尼单药组：细胞略变圆，形态改变，空泡和颗粒增多，细胞间隙增大。

Gefitinib monotherapy group : Cells slightly rounded , shape changed , cavitation and particle growed in number , the cell gap increased .

然而，无论是抗肿瘤治疗开始后的整体生存率，还是吉非替尼治疗后无恶化生存率在上述两组病人中并无明显差异。

However , neither overall survival after the start of antitumor therapy nor progression-free survival after gefitinib therapy was significantly different between groups .

背景：此前的无对照研究显示肺癌一线治疗联合吉非替尼治疗非小细胞肺癌是有效的。

Background : Previous , uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non – small-cell lung cancer .

接着，我们检测配体依赖的基于受体表达，磷酸化，二聚化的细胞对吉非替尼敏感的机制。

Subsequently , we monitored the ligand-dependent HER profiles based on receptor expression , phosphorylation , and dimerization in conjunction with measurements of cellular susceptibility to gefitinib .

与传统化疗药物相比，吉非替尼具有瞄准特定的分子靶点、不良反应小和特异性强等优点。

Gefitinib has a more favorable tolerability profile and less adverse effect than traditional chemotherapy agents in the treatment of tumor since it aim directly at tumour cells .